NCT05966350 (AGO) is a clinical trial of Diagnosis of sensitive neuronopathy - phase 1 in Autoimmune Diseases, sponsored by Centre Hospitalier Universitaire de Saint Etienne.

Who is sponsoring NCT05966350?

NCT05966350 is sponsored by Centre Hospitalier Universitaire de Saint Etienne.

What drugs are being tested in NCT05966350?

Interventions in NCT05966350: Diagnosis of sensitive neuronopathy - phase 1, Diagnosis of sensitive neuronopathy - phase 2, Comparison with Chi2 method, Comparison of data with parametric Test (T-test), Comparison of data with non-parametric test (ANNOVA).

What condition does NCT05966350 study?

NCT05966350 studies Autoimmune Diseases.

Is NCT05966350 still recruiting?

NCT05966350 is currently completed. Last updated 28 July 2023.

Last reviewed 2023-07-28 · How we verify

NCT05966350: AGO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-Argonaute Antibodies for the Diagnosis of Sensory Neuronopathies

Completed Last updated 28 July 2023

What this trial tests

trial testing Diagnosis of sensitive neuronopathy - phase 1 in Autoimmune Diseases in 630 participants. Completed in 27 January 2023.

Timeline

27 May 2021

Primary endpoint
27 January 2023

27 January 2023

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Saint Etienne
Status	Completed
Study type	OBSERVATIONAL
Enrollment	630
Start date	27 May 2021
Primary completion	27 January 2023
Estimated completion	27 January 2023
Sites	1 location across France

Drugs / interventions tested

Diagnosis of sensitive neuronopathy - phase 1
Diagnosis of sensitive neuronopathy - phase 2
Comparison with Chi2 method
Comparison of data with parametric Test (T-test)
Comparison of data with non-parametric test (ANNOVA)

Conditions studied

Autoimmune Diseases — all drugs for Autoimmune Diseases →

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

18 and older, any sex, with Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Argonaute (AGO) proteins have been described as the target of antibodies in several autoimmune diseases including Sjögren Syndrome (SS). Sensory neuronopathies (SNN) are disorders affecting neurons in the dorsal root ganglia that may depend on an inflammatory process. However, identifying these cases needs the availability of specific biomarkers. The aim of this study is to test the prevalence of anti-AGO antibodies in a population of patients with Sensory neuronopathies (SNN) with and without associated autoimmune disease in comparison with other peripheral neuropathies to determine how anti-AGO antibodies may help the identification of potentially dysimmune Sensory neuronopathies (SNN).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Autoimmune Diseases

Currently open trials in the same condition.

NCT06948110 — Deciphering the Genetic Architecture of Autoimmune Diseases · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07408336 — Clinical Study of AFN50 Injection in the Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07283315 — Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia · EARLY_PHASE1 · recruiting
NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

NCT07326579 — Effects of a Sleep Education Program on the Health Status of Healthcare Workers Working 12-hour Alternating Day-night Sh · NA · not yet recruiting
NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07483710 — Association Between Muscle L3 CT Scan Muscle Derived Parameters of Muscle Function Upon Intensive Care Unit Admission an · NA · not yet recruiting
NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
NCT07344298 — Less is Better? Effectiveness of a Short Local Vibration Protocol on Neuromuscular Function · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05966350 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Saint Etienne
Last refreshed: 28 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05966350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing